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Background: Numerous rodent models of photoreceptor degeneration have been developed for the study of
visual function. However, no viable model has been established in a species that is more closely related to Homo
sapiens. Here, we present a rabbit model of monocular photoreceptor degeneration.
Methods: We tested 2 chemicals, verteporfin and sodium nitroprusside (SNP), for developing a 1-eye limited
photoreceptor degeneration model in pigmented rabbits. After the intravenous injection of verteporfin, the retina
was exposed to light from a halogen lamp for 0, 10, 30, or 60 min. Alternately, 100 μL of various concentrations of
sodium nitroprusside (0.1 mM, 0.5 mM, and 1 mM) were intravitreously injected into the rabbit eye. Retinal
degeneration was evaluated by fundus photography, electroretinogram (ERG), and histological examinations.
Results: Fundus photographs of animals in the verteporfin- or SNP-treated groups showed evidence of retinal
degeneration. The severity of this degradation depended on the duration of light exposure and the concentration
of SNP administered. The degeneration was clearly limited to the light-exposed areas in the verteporfin-treated
groups. Extensive retinal atrophy was observed in the SNP-treated groups. The a- and b-wave amplitudes were
dramatically decreased on the ERGs from SNP-treated groups. Histological examination revealed that either
verteporfin or SNP induced severe photoreceptor degeneration. High-dose SNP treatment (1 mM) was also
associated with inner retinal layer degeneration.
Conclusions: Both SNP and verteporfin clearly caused photoreceptor degeneration without any effect on the
contralateral eye. These compounds therefore represent valuable tools for the empirical investigation of visual
function recovery. The findings will inform guidelines for clinical applications such as retinal prostheses, cell-based
therapy, and gene therapy.
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Retinitis pigmentosa (RP) is a degenerative disease of the
retina that causes night blindness and ultimately a loss
of peripheral and central vision [1]. Several genes re-
sponsible for RP have been identified, most of which are
related to phototransduction pathways. However, these
findings have not yet led to the discovery of effective
treatments or prevention strategies. Retinal prostheses
that elicit phosphenes by stimulating the remaining* Correspondence: htomita@iwate-u.ac.jp
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reproduction in any medium, provided the orretinal neurons have been studied as potential tools to
restore vision in these patients. Recently, clinical trials
performed in the U.S. [2], Germany [3], and Japan [4]
have reported successful results. Sasai et al. successfully
created a complete, three-dimensional retina in vitro
using embryonic stem cells [5]. Our group as well as in-
vestigations by Bi et al. have used gene therapy to restore
vision [6-10]. Numerous similar efforts represent add-
itional potential tools on the horizon of vision recovery.
Various rodent models of photoreceptor degeneration
have been developed for the study of visual function.
The Royal College of Surgeons (RCS) rats [11] carry a
mutation in the Mertk gene that induces spontaneous
photoreceptor degeneration [12]. Continuous light ex-
posure is another technique used to investigate thetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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[13], P23H [14,15], rd, and rds [16,17] transgenic rats
harbour mutations associated with human RP. Thus far,
however, no model has been established in higher ani-
mals. The rabbit model of photoreceptor degeneration
presented here would allow for experiments on compli-
cated behavioural tasks that more closely simulate visual
function in humans.
Here, we report 2 methods for generating a rabbit model
of monocular photoreceptor degeneration. Verteporfin
(Novartis AG, Bülach, Switzerland) is a photosensitising
dye that is used clinically, without any adverse effects, for
patients with subfoveal choroidal neovasucularisation
(CNV). However it has been reported in pre-clinical stud-
ies that overdoses of verteporfin and/or extended light ex-
posure induce photoreceptor and RPE cell damage [18].
Here, verteporfin is used for the purpose of the induction
of local photoreceptor degeneration. Sodium nitroprusside
(SNP) is used for the treatment of hypertension [19]. SNP
breaks down in the blood and releases nitric oxide (NO),
which works as a vasodilator. In the retina, excess NO in-
duces photoreceptor degeneration. The intravitreous injec-
tion of SNP induces extensive photoreceptor degeneration.
Both verteporfin and SNP induce marked photorecep-
tor degeneration without any effect on the contralateral
eye. The benefits of a monocular model of photorecep-
tor degeneration include use of the fellow eye as a con-
trol, which reduces the number of animals to be utilised
for the experiment. Finally, the relatively large size of a
rabbit vs. rodent eye renders surgery less challenging.
Methods
Verteporfin was applied according to the manufacturer’s
protocol, except for slight modifications. In our study,
we used a halogen reflector lamp as the light source. In
brief, a vial containing 2 mg of verteporfin was dissolved
in 7 mL of sterile distilled water, then diluted with a 5%
Otsuka glucose solution (Otsuka Pharmaceutical Co.,
Ltd, Tokyo) to adjust the concentration to 0.1 mg/mL.
The solution (0.5 mg/kg) was injected intravenously
at a speed of 1 mL/min. SNP was dissolved in saline,
and various concentrations of SNP were injected
intravitreously into the pigmented rabbit eyes.
Eighteen, male Dutch rabbits (kbl: Dutch, 1.5–2.0 kg)
were used for experiments. These animals were used in
accordance with the ARVO Statement for the Use of
Animals in Ophthalmic and Vision Research and the
Guidelines for Animal Experiments of Tohoku Univer-
sity. All animal experiments were conducted with the
approval of the Animal Research Committee, Graduate
School of Medicine, Tohoku University.
The rabbits were anesthetised by the intramuscular in-
jection of a mixture of ketamine (66 mg/mL) and xylazine
(33 mg/kg). To induce retinal degeneration usingverteporfin, the retina was exposed to light from a halogen
reflector lamp located 10 mm from the cornea (40000 lux;
KL 2500 LCD, Carl Zeiss, Göttingen) after dilating the
pupils with 1% atropine and 2.5% phenylephrine hydro-
chloride (Mydrin P; Santen Pharmaceutical Co., Ltd.,
Osaka, Japan). For the second model, after oxybuprocaine
hydrochloride (0.4% Benoxil ophthalmic solution; Santen
Pharmaceutical Co., Ltd., Osaka, Japan) was applied
topically to the eye, using an operating microscope, a
small incision was made in the conjunctiva to expose the
sclera, and 100 μl of SNP solution was injected
intravitreally through the ora serrata with a 30-gauge nee-
dle. Two weeks later, fundus photographs were obtained
using a handy fundus camera (Genesis Df; Kowa, Tokyo,
Japan). ERG recordings were obtained 1 month after the
treatment.
ERGs were recorded using a Neuropack (MEB-9102;
Nihon Kohden, Tokyo, Japan) as previously described
[10]. Briefly, rabbits were dark-adapted overnight, pupils
were dilated with 1% atropine and 2.5% phenylephrine
hydrochloride, and the corneas were anaesthetised with
0.5% proparacaine hydrochloride. Small contact lenses
with gold wire loops were placed on both corneas, and a
silver wire reference electrode was placed subcutane-
ously between the eyes. Flash light stimuli with a dur-
ation of 10 ms were generated by pulse activation of a
white LED. Full-field scotopic ERGs were recorded,
band-pass filtered at 0.3–500 Hz, and averaged for 5 re-
sponses at each light intensity. The ground electrode clip
was placed on the tail. Photic stimuli were generated by
pulse activation of a white light-emitting diode (LED). A
white LED (7500 Kelvin) was used for white stimuli; fur-
ther, because a white colour LED includes multiple
wavelengths, Kelvins were generally used as the unit of
measurement.
The analysis of retinal morphology in verteporfin- and
SNP-treated eyes was performed as previously described
by Tomita et al. [9]. In brief, rabbits were sacrificed by
the intravenous injection of pentobarbital. The eyes were
enucleated, fixed, and embedded in paraffin. Three
micrometre-thick sections of the retina were cut along
the horizontal meridian and stained with haematoxylin
and eosin.
Statistical analysis was performed using GraphPad
Prism software (GraphPad Software, San Diego, CA).
The criterion for statistical significance was p < 0.05.
The statistical analysis was performed using an unpaired
t-test.
Results
There were no obvious changes between untreated-
(Figure 1A) and verteporfin-treated retinas without
light exposure (Figure 1B). Light exposure following
verteporfin treatment (Figure 1C-E) or the intravitreous
Figure 1 Fundus photographs taken 2 weeks after treatment with PDT or intravitreal SNP. The control fundus is shown in A. PDT was
performed with 0.5 mg/kg verteporfin and a halogen reflector lamp for 0 (B), 10 (C), 30 (D), or 60 (E) min. One hundred microliters of SNP (F: 0.1 mM,
G: 0.5 mM, H: 1 mM) was injected intravitreously into a rabbit eye. Arrows and arrowheads indicate the pigmentation and the area of severe
degeneration, respectively. Lesions are clearly demarcated by a broken line.
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The degree of atrophy depended on the duration of light
exposure or SNP concentration. When the verteporfin-
treated retina was exposed to light, for even as little as 10
min, pigmentation of the retinal pigment epithelial (RPE)
cells was observed clearly (Figure 1C). As the duration
of light exposure was extended, the pigmentation be-
came more obvious and was labelled as RPE atrophy
(Figure 1C-E). The lesions induced by verteporfin with
light exposure were clearly restricted to the area exposed
to light (Figure 1D). However, the degeneration induced
by SNP extended to the peripheral retina (Figure 1F-H).
Fluorescence angiography showed some haemorrhagearound the optic nerve in eyes injected with 1 mM of SNP
(Figure 1H).
Amplitudes (a- and b-waves) of ERGs in verteporfin-
treated eyes (Figure 2B-D) were decreased slightly
compared to those in the untreated eye (Figure 2A).
The b-wave amplitude declined with the duration of light
exposure. In SNP-treated eyes, amplitude decreased with
increasing SNP concentrations (Figure 2E-G). Even after
injecting only a 0.1-mM solution of SNP (Figure 2E), ERG
b-wave amplitudes were decreased markedly (Figure 2H).
Verteporfin treatment without light exposure did not
induce photoreceptor degeneration (Figure 3B). How-
ever, degeneration of the neural retina (primarily
Figure 2 The typical waveforms of electroretinogram (ERG) responses evoked by a white flash (duration: 10 ms; light intensity: 10,
100, and 1000 lux, top to bottom). Waveforms with no treatment are shown in A. Eyes were submitted to PDT with light exposure (B: 10 min,
C: 30 min, D: 60 min) or SNP injection (E: 0.1 mM, F: 0.5 mM, G: 1 mM). Comparison of b-wave amplitudes in eyes treated with either verteporfin
or SNP (H). Data are shown as mean ± S.D., n = 3, *, #, $; p < 0.05, **, ##, $$; p < 0.01, unpaired t-test.
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exposure (Figure 3C–F). In the SNP-induced degeneration
model, the lesion included the inner and photoreceptor
layers of the peripheral retina as well (Figure 3G-I).
Discussion
The photosensitising dye verteporfin is widely used as
part of photodynamic therapy (PDT) for the treatmentof CNV. However, PDT is not purely selective for the
choroid and may induce damage to the retina [18]. In
primates [20,21] and rabbits [22], PDT induces dose-
dependent damage to photoreceptors and RPE cells. Fol-
lowing the absorption of specific wavelengths of energy
[23], verteporfin generates oxygen radicals, which are
toxic to photoreceptor and RPE cells. In our study, fun-
dus photography revealed that the photoreceptor
Figure 3 Histological evaluations of photoreceptor degeneration after either PDT treatment or SNP injection. Retinal histology without
treatment is shown in (A). PDT was performed with 0.5 mg/kg verteporfin and a halogen reflector lamp for 0 (B), 10 (C), 30 (D), or 60 (E, F) min.
The bar in the figure (F) indicates the area exposed to light. One hundred microlitters of SNP (G: 0.1 mM, H: 0.5 mM, I: 1 mM) are injected
intravitreously injected into a rabbit eye.
Isago et al. BMC Ophthalmology 2013, 13:19 Page 5 of 7
http://www.biomedcentral.com/1471-2415/13/19damage triggered by exposure to light after the intraven-
ous injection of verteporfin was limited to areas that
were exposed to light.
NO is released from SNP primarily through photo-
chemical reactions [24] and by various reducing metabo-
lites including thiols, which are contained in biological
organelles such as microsomes [25]. NO is involved in
numerous retinal functions [26,27]. Endogenous NO
enhances the cone response during light-adaptation
[28,29], sometimes leads to retinal toxicity (e.g., photo-
receptor degeneration) [30] and contributes to ischemia-
induced injury [31-33]. Under normal conditions, in
contrast to ischemia or continuous or intense light ex-
posure, the severity of induced retinal degeneration de-
pends on local NO levels. The primary target of NO
toxicity seems to be the outer retinal layers; even low-
dose applications of NO (0.1 mM) induced degeneration
in the outer retinal layers. The mechanisms of thedegeneration induced by NO remain unclear. Several re-
ports have outlined the relationship between NO and
phagocytosis in RPE cells [34]. Becquet et al. [35]
showed that NO inhibits the cGMP-independent phago-
cytosis of photoreceptor outer segments in vitro. Our la-
boratory found that NO inhibited cathepsin S activity
via S-nitrosylation [27], which resulted in the accumula-
tion of lipofuscin [36]. The degeneration induced by
preventing rod outer segment phagocytosis is most likely
gradual. Other factors may come into play to accelerate
the process. Peroxynitrite formed from NO and the
superoxide anion (O2-) or hydroxyl radical (OH-) has
highly toxic effects on neuronal cells [37]. The excessive
consumption of oxygen by photoreceptors generates
high levels of superoxide anion (O2
-) and hydroxyl radical
(OH-). Free radicals accelerate photoreceptor degener-
ation; conversely, free radical scavengers inhibit the
photoreceptor degeneration caused by continuous light
Isago et al. BMC Ophthalmology 2013, 13:19 Page 6 of 7
http://www.biomedcentral.com/1471-2415/13/19exposure [38,39]. Peroxynitrite might be a major factor
in the acute photoreceptor degeneration induced by NO.
NO is a gas of low molecular weight; intravitreous injec-
tions are easily slowed by the viscous vitreous as they
spread across the retina. However, once the gas has
reached the retina, NO can pass through the inner
retinal layers easily and cause toxic effects.
Conclusions
Our results highlight 2 methods for the induction of
photoreceptor degeneration in a rabbit model: verteporfin
with light exposure and SNP. In the verteporfin-light ex-
posure model, photoreceptor degeneration can be limited
to the area exposed to light. This model is useful for the
induction of local photoreceptor lesions, such as those
that occur in age-related macular degeneration. In con-
trast, SNP induces photoreceptor degeneration through-
out the entire retina. Both models are supported in large
animals and may be useful for regenerative research, such
as that directed toward the development of retinal pros-
theses, iPS transplantation, and gene therapy.
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